… number of medical indications besides psoriasis. Here, we review the specific niches where
TNF-α inhibitors and ustekinumab may have utility compared to other biologic therapies. …

… of psoriasis, IL-12/23 inhibitors were developed for treatment of … The cytokine dysregulation
of TNF-alpha, IL-6, and, IL-17 … the therapeutic potential of ustekinumab in psoriasis vulgaris …

… utility of ustekinumab in non-pustular palmoplantar psoriasis … after 172 weeks of ustekinumab
therapy, and rapid improvement … the utility of other biological drugs with ustekinumab in the …

… ’s disease, plaque psoriasis and pediatric ulcerative colitis. … , their utility as diagnostics or
therapeutics will grow as well. … pegol (Cimzia) and etanercept (Enbrel). Several studies have …

… such that we now have a plethora of therapies at our disposal. … treatments, small molecule
drugs and biologics used in the … not report significant risk of melanoma for ustekinumab. Two …

… or had contraindications to at least one anti-TNF-alpha. In this study, the … according to the
psoriasis therapeutic schedule of … pain/utility/handicap score decreased from 1 to 2. Citation78 …

… This study aimed to investigate the utility of these markers for … plaque psoriasis, who received
ustekinumab therapy were … such as IL-6 and TNF-alpha compared to NLR and that it was …

… Seven studies proved its role in psoriasis, axial … even with conflicting data regarding its
utility in clinical practice. The … that ustekinumab is more cost-effective in the TNF-alpha-inhibitor …

… the psoriasis immune response [14]. Through the inhibition of IL-12 and IL-23, ustekinumab
… this research including “Psoriasis”, “biological treatment”, “TNF-alpha inhibitor”, “IL-12/IL-23 …

… the treatment response to other bDMARDs, such as ustekinumab, but the evidence is mostly
available in psoriasis … The research utility of synovial biomarker discovery relies on the …